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Wild-type adenovirus type 5 eliminates p53 through the
E1B-55 kDa and E4-34 kDa gene products. Deletion or
mutation of E1B-55 kDa has long been thought to confer
p53-selective replication of oncolytic viruses. We show here
that infection with E1B-defective adenovirus mutants induces
massive accumulation of p53, without obvious defects in p53
localization, phosphorylation, conformation and oligomer-
ization. Nonetheless, p53 completely failed to induce its
target genes in this scenario, for example, p21/CDKN1A,
Mdm2 and PUMA. Two regions of the E1A gene products
independently contributed to the suppression of p21
transcription. Depending on the E1A conserved region 3,
E1B-defective adenovirus impaired the ability of the
transcription factor Sp1 to bind the p21 promoter. More-
over, the amino terminal region of E1A, binding the acetyl
transferases p300 and CREB-binding protein, blocked p53
K382 acetylation in infected cells. Mutating either of these
E1A regions, in addition to E1B, partially restored p21
mRNA levels. Our ﬁndings argue that adenovirus attenuates
p53-mediated p21 induction, through at least two E1B-
independent mechanisms. Other virus species and cancer
cells may employ analogous strategies to impair p53 activity.
Oncogene (2011) 30, 865–875; doi:10.1038/onc.2010.461;
published online 11 October 2010
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Introduction
The tumor suppressor p53 was initially identiﬁed and
characterized by its interactions with viral oncoproteins.
E1A and E1B represent the key oncogenes of adenovirus;
E1A proteins bind the retinoblastoma family of proteins,
whereas E1B-55kDa forms a speciﬁc complex with p53. In
cells infected with adenovirus type 5, p53 activity is
antagonized by E1B-55kDa and E4-34kDa. E1B-55kDa
inhibits p53-mediated transcriptional activation. Together
with E4-34kDa, it also promotes ubiquitination and
proteasomal degradation of p53, presumably helping to
avoid the premature death of infected cells (Levine, 2009).
Many attempts were made to construct adenoviruses
capable of replicating selectively in cancer but not in
normal cells. Bischoff et al. (1996). hypothesized that E1B-
55kDa-deleted viruses are not able to inactivate p53 and
therefore, should replicate selectively in cells with mutated/
null p53 status, but not in cells bearing a wild-type p53 gene.
This idea made E1B-deleted viruses a potentially attractive
tool for cancer therapy. Some studies initially supported the
idea of a E1B-55kDa-deleted virus, ONYX-15, replicating
in p53-deﬁcient tumor cells (Heise et al., 1997). However,
more recent reports addressed virus replication in a large
variety of cell species with different p53 status; the
observations suggested that infection with viruses lacking
E1B-55kDa results neither in selective replication nor in
selective cell killing in the absence of functional p53
(Goodrum and Ornelles, 1998; Rothmann et al., 1998;
Turnell et al., 1999). Importantly, we and others have
previously observed impaired p53 function in adenovirus-
infected cells, even when E1B-55kDa was deleted (Ray
et al., 1989; Hobom and Dobbelstein, 2004; O’Shea et al.,
2004). Identifying the underlying reasons for continued
p53 attenuation in this context may not only explain
adenovirus-cell interactions, but may also point out
general pathways of p53 regulation.
In this study, we have investigated the molecular
pathways of p53 attenuation by adenoviruses deleted for
E1B-55kDa. Despite p53 accumulation, p53-responsive
genes were not induced. Surprisingly, the adenovirus E1A
proteins prevented the activation of p21 through p53 by
two distinct mechanisms: E1A blocked the acetylation of
p53 at K382 and it reduced the amount of promoter-
bound Sp1, a transcription factor that cooperates with p53.
Both the acetylations at K382 and transcription factor Sp1
are required for transcriptional activation of a number of
p53 targets. Therefore, we propose that adenovirus may
employ at least two distinct mechanisms of p53 inactiva-
tion that depend on E1A but not E1B.
Results
E1B-55 kDa mutant adenoviruses stabilize and
accumulate inactive p53
To assess the inﬂuence of adenovirus infection on p53
levels and activity, A549 cells (containing wild-type p53)
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were infected with adenovirus mutants bearing a
deletion of E1B-55 kDa (dl338) or a point mutation
(R240A) that disrupts its interaction with p53 (Shen
et al., 2001). Wild-type adenovirus (dl309) was used as a
control. p53 accumulated to high amounts 24 h after
infection with dl338 or R240A (Figure 1a), but not with
a replication-defective, E1-deleted virus vector (Supple-
mentary Figure S1A). Wild-type virus suppressed p53
levels below detectability, in agreement with the
essential role of E1B-55 kDa in p53 degradation
(Figure 1a). However, the elevated levels of p53 in
response to dl338- or R240A-infection did not increase
the amount of its target gene products p21 and Mdm2;
on the contrary, those were downregulated after
infection (Figure 1a), as found earlier in similar
experiments, even when the cells had been treated with
camptothecin to trigger a DNA damage response
(Hobom and Dobbelstein, 2004). To understand the
mechanisms of p53 accumulation, we performed quanti-
tative PCR analysis of p53 mRNA from infected cells,
but did not detect changes comparable to the protein
levels (Figure 1b). Instead, cycloheximide chase analyses
indicated the stabilization of the p53 protein upon
infection with E1B-55 kDa-deﬁcient viruses (Figure 1c).
Infection with E1B-55 kDa-mutant adenoviruses does not
detectably affect the localization, conformation,
phosphorylation, or oligomerization of p53
To address whether E1B-55 kDa-mutant viruses are
inactivating p53 by mislocalization, we detected p53 by
immunoﬂuorescence. p53 was found in the nucleus of
cells infected with dl338 and R240A (Figure 2a); the
staining was evenly distributed and did not merge with
viral replication centers, as detected by antibodies to the
E2A DNA binding protein. Thus, the lack of p53
activity cannot be attributed to improper localization in
infected cells.
For its function as a transcription factor, p53 requires
an active conformation, which is disrupted by cancer-
associated mutations. These structural mutants display
epitopes that are normally hidden and one of these are
reactive with the monoclonal antibody 240. To deﬁne
whether E1B-55 kDa-deleted viruses accumulate p53 in
an inactive or mutant-like conformation, immunopreci-
pitation analysis with antibodies, recognizing wild-type
(1620) versus mutant (240) conformation of the protein,
was performed. We thereby found that p53 retains wild-
type conformation after infection (Figure 2b).
Phosphorylations of p53 at Ser-15 (by DNA-depen-
dent protein kinase and ataxia telangiectasia mutated/
ataxia telangiectasia-mutated and rad3-related) and Ser-
46 (by homeodomain-interacting protein kinase 2)
contribute to p53 activity (Bode and Dong, 2004). We
detected these modiﬁcations on p53 from infected cells
by immunoblot analysis, to a degree comparable to
camptothecin-treated cells (Figure 2c).
p53 exists mostly as a tetramer and oligomerization of
p53 is required for its function. We tested the ability of
p53 to form oligomers after infection with E1B-55 kDa-
mutant viruses, using glutaraldehyde cross linking,
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Figure 1 Stabilization and accumulation of inactive p53 after
infection with E1B-55 kDa mutant adenoviruses. A549 cells were
mock-infected, infected with-wild type adenovirus (dl309) or with
adenovirus mutants dl338 (lacking E1B-55 kDa) and R240A
(carrying a substitution R–A at position 240 of E1B-55 kDa,
resulting in strongly reduced p53 binding), at a multiplicity of
infection (MOI) of 20. For a positive control, cells were treated
with the DNA-damaging topoisomerase inhibitor camptothecin
(CPT). Twenty-four hours after infection, the cells were harvested.
(a) p53, p21 and Mdm2 proteins were detected by immunoblot
analysis with the corresponding antibodies; b-actin and HSC70
were stained as loading controls. (b) Total RNA was isolated,
reverse transcribed and subjected to real-time PCR analysis with
primers amplifying p53 cDNA. Results were normalized to
GAPDH mRNA. Mean values from three independent experi-
ments are shown with standard deviations. (c) Twenty-four hours
after infection, the cells were treated with the inhibitor of
translation cycloheximide for the indicated time intervals, or with
the dimethyl sulfoxide solvent alone for 4 h. p53 levels were
determined by immunoblot analysis. Note that a longer exposure
was used in the case of mock-infected cells.
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SDS–PAGE and immunoblot analysis. p53 from in-
fected cells was compared with transiently expressed
wild-type p53 or a mutant that lacks a functional
oligomerization domain (p53DO; D327-347 (Atz et al.,
2000)). As shown in Figure 2d, p53 from infected cells,
as well as wild-type p53 but not p53DO, could be
detected at molecular weights (around 55 and 130 kDa)
that corresponded to monomeric and dimeric p53. This
argues against the idea that the virus disturbs the
oligomerization of p53.
Taken together, all properties of p53 under study were
compatible with its activity. Nonetheless, p53-mediated
transcriptional activation is blocked by E1B-55 kDa
mutant adenoviruses.
E1A-deletion mutants differentially regulate
p53-dependent gene expression
Next, we assessed whether the E1A family of proteins is
involved in the inactivation of p53 upon infection with
E1B-55 kDa-deleted virus. The major products obtained
by splicing of the primary E1A mRNA transcript are
E1A-12S and 13S. These proteins differ only in a 46-
amino-acid domain, termed conserved region 3 (CR3),
that belongs exclusively to E1A-13S. E1A was reported
to affect p53 levels and activity, but this was mostly
addressed upon transient overexpression of E1A
through plasmid transfection (Lowe and Ruley, 1993;
Steegenga et al., 1996).
To understand the involvement of E1A proteins in
p53 inactivation during virus infection, we compared a
panel of Ad5 mutants carrying E1A mutations com-
bined with a deletion or mutation of E1B (Figure 3a).
These mutants also lack the antiapoptotic E1B-19 kDa
protein. However, we observed that the additional
deletion of E1B-19 kDa did not affect p21 expression
in the context of a E1B-55 kDa-mutant virus (Supple-
mentary Figure S1B). After infection of A549 cells, we
analyzed the expression of two p53-activated genes, p21
and mdm2, by quantitative RT–PCR (Figure 3b, right).
Interestingly, only viruses expressing E1A-13S reduced
p21 and mdm2 mRNA levels more than 10-fold,
whereas mutants bearing only E1A-12S (despite equal
or greater overall E1A protein levels) failed to repress
p53-responsive genes. Instead, E1A-12S-only viruses
were upregulating p21 and mdm2 mRNA two- to
sixfold, compared with mock-infected cells (Figure 3b,
right). A similar pattern was observed in non-trans-
formed cells (Supplementary Figure S2) and also for the
transcription of PUMA, a proapoptotic target gene of
p53 (Figure 3c). Of note, dl520-E1B–, a mutant lacking
E1A-13S, was upregulating p21 mRNA, but not p21
protein levels (Figure 3b). In contrast, p21 protein levels
were restored upon infection of cells with viruses that
expressed E1A-mutants with deletions in the amino
terminal portion or in the CR 2 (dl1101-E1B–, dl1107-
E1B– and dl0107-E1B–). This argues that adenovirus
infection interferes with p21 translation and/or protein
stability by unknown mechanisms that depend on
additional E1A activities. In any case, our results show
that E1A-13S, but not E1A-12S, blocks the accumulation
of p21 mRNA. p21 pre-mRNA levels were responding to
the virus mutants much like the fully processed mRNA
(Figure 3d), arguing that the regulation by E1A-13S
occurs at the level of transcription, not RNA processing.
Viruses with or without the deletion of E1A-13S differ
in their ability to replicate (Carlock and Jones, 1981),
and accordingly, virus replication centers were observed
in a lower percentage of cells upon infection with dl338
versus dl520-E1B– (Supplementary Figure S3, A and B).
However, this difference could be adjusted by treating
the dl338-infected cells with an inhibitor of DNA
synthesis, cytosine-arabinoside (AraC; Supplementary
Figure S3C). Similarly, the two- to threefold difference
between dl338 and dl520-E1B– with regard to early and
late mRNA expression levels could be adjusted by AraC
treatment (Supplementary Figure S4). Importantly, and
despite the fact that AraC increases p21 mRNA levels in
mock-infected cells, we still observed that p21 mRNA
was suppressed upon infection by dl338 regardless of
AraC treatment (Supplementary Figure S5). We con-
clude that the failure of dl520-E1B– to interfere with p21
mRNA accumulation is not due to impairments in virus
replication. Furthermore, dl520-E1B– reached hexon
levels similar to dl338 after 36 h after infection
(Supplementary Figure S6A), but p21 mRNA levels
remained far higher in dl338- than in dl520-E1B–
infected cells for at least 48h (Supplementary Figure S6B).
To exclude a role for E4orf6 in differential p53 regulation
(Dobner et al., 1996), we assessed p21 mRNA levels
upon infection with a virus that carries E1A-13S, but l
acks both E1B-55kDa and E4orf6. In this case, p21
mRNA was still reduced compared with mock-infected
cells (Supplementary Figure S7). Taken together, these
results further support the idea that the CR3 domain of
E1A suppresses p21 mRNA synthesis in adenovirus-
infected cells.
E1A-13S is responsible for removing Sp1 from the p21
promoter
Despite accumulation of massive amounts of p53
(Figure 4a), both dl520-E1B– and dl338 only permitted
low p53-DNA-association, comparable to the non-
infected samples, as revealed by chromatin immunopre-
cipitation (Figure 4b). In contrast, camptothecin en-
riched p53 binding to the p21 promoter more than 10-
fold. We conclude that infection with E1B-55 kDa-
deleted adenovirus can generally decrease p53–DNA
complex formation, but this does not explain the
differential p53 target gene expression upon infection
with dl520-E1B– versus dl338.
The transcription of p21 and Mdm2 also depends on
the transcription factor Sp1 acting synergistically with
p53 (Lagger et al., 2003, Zhao et al., 2006). The E1A-
13S protein, in turn, was reported to bind Sp1 within its
CR3 region (Liu and Green, 1994). Thus, we hypothe-
sized that E1A-13S may impair the function of Sp1 in
p21 transactivation. The viruses dl520-E1B– and dl338
enhanced the Sp1 protein levels to a similar extent
(Figure 4a). However, chromatin immunoprecipitation
of Sp1 retrieved signiﬁcantly less p21 promoter DNA,
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when the cells were infected with dl338, containing
E1A-13S, compared with dl520-E1B–, bearing only
E1A-12S (Figure 4c). Similarly, RNA polymerase II
associated poorly with the p21 transcription start site
after infection with dl338, but more efﬁciently upon
infection with dl520-E1B–(Supplementary Figure S8),
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suggesting that the presence of E1A-13S reduces the
formation of a functional transcription initiation com-
plex. Finally, a pharmacological antagonist of the Sp1-
DNA-interaction, mithramycin A (Ray et al., 1989),
suppressed p21 mRNA levels in dl520-E1B– infected
cells (Figure 4d); this further argues that the main-
tenance of Sp1 activity is at least one reason why viruses
lacking E1A-13S fail to suppress p21 mRNA synthesis.
The amino terminal portion of E1A is required to abolish
p53 acetylation at K382
Acetylation of p53 at lysine residues can activate
transcription. Immunoblot analysis with antibodies
recognizing p53 acetylated at position K382, after
infection with dl338 or dl520-E1B–, showed that both
viruses prevent the acetylation of p53 at this residue
even in the presence of the DNA-damaging drug
camptothecin (Figure 5a). Interestingly, however, infec-
tion with adenovirus mutant dl1101-E1B–, bearing an
amino terminal mutation of E1A that prevents its
binding to the histone acetyltransferase p300, allowed
acetylation of p53 at K382 (Figure 5a). Another pair of
virus recombinants, differing only with regard to the
amino terminal region of E1A, showed the dependence
of p53 acetylation on the mutation of E1A (Supplemen-
tary Figure S9). Thus, p300 binding by E1A represents a
plausible mechanism for the missing p53 acetylation in
infected cells.
To understand whether acetylation of p53 at K382 is
required for p53-mediated transactivation even in the
presence of E1A-13S, we analyzed p21 mRNA levels
after infection with a recombinant adenovirus that
combines the mutations R2G in E1A (abolishing p300
binding) and R240A in E1B-55 kDa (deleting p53
binding). We had previously observed reduced p21
protein levels upon infection with this virus (Shen et al.,
2001). However, this does not necessarily imply p21
mRNA suppression (cf. Figure 3b, dl520-E1B–). Re-
markably, the E1A-R2G/E1B-R240A double mutant
virus accumulated p53 with acetylated at K382
(Figure 5b) and allowed p21 transcription at least to
the level of mock-infected cells, whereas the E1B-R240A
single mutant suppressed p21 mRNA levels threefold
(Figure 5c). This argues that the impairment of p53
acetylation by E1A represents another way by that the
virus attenuates p53 activity, independently of E1A-
CR3 and E1B-55 kDa.
Discussion
The presence of direct p53 antagonists in small DNA
tumor viruses has led to the discovery of p53 in the ﬁrst
place. It therefore came as a surprise that adenoviruses
lacking p53-binding E1B-55 kDa still abolish the efﬁ-
cient expression of p53-responsive genes, despite the
accumulation of p53 in unusually high amounts.
Our results largely explain this seeming contradiction.
In addition to E1B-55 kDa, the E1A gene products
also antagonize p53 during infection. Although E1A
proteins do not form detectable complexes with p53,
they avoid p53 activity at least in two ways. Firstly,
the E1A CR3 region mediates p53 inhibition, and
it interferes with Sp1-promoter-interactions. Secondly,
E1A interferes with p53 acetylation through its amino
terminal, p300-binding region. Both activities of
E1A block the transcription of the major p53 target
p21 even in the absence of a direct p53 antagonist
(Figure 5d). It should be pointed out that this scenario
reﬂects the situation of an infected cell, not oncogenic
transformation by the virus E1 region. In the latter
case, E1A induces apoptosis largely through p53
(Debbas and White, 1993). However, infected cells
contain much higher amounts of virus proteins than
transformed cells, with little time for the host cell
to adapt the levels of cellular E1A-binding proteins.
We propose that this scenario leads to p53-attenuation
by E1A.
Inactivation of p53 through E1A-13S
The CR3 region of E1A turned out as a major
determinant of how p53-responsive genes are tran-
scribed upon adenovirus infection in the absence of
E1B. Only virus mutants that retained the E1A-13S
isoform—the sole isoform containing CR3—were still
blocking the expression of such genes. Viruses without
E1A-13S still interfered with p53 acetylation, but
nonetheless allowed p53-induced gene expression. CR3
has long been known for its capability of interacting
with the transcription factor Sp1 (Liu and Green, 1994),
raising the possibility that E1A-13S antagonizes p53 by
interfering with Sp1 activity. In agreement with this
model, Sp1-DNA interaction was signiﬁcantly dimin-
ished as a function of E1A-13S, and pharmacological
inhibition of Sp1 reduced p21 levels when E1A-13S was
absent (Figure 4). These observations do not exclude the
Figure 2 Post-translational modiﬁcations of p53 in cells infected with E1B-55 kDa-mutant adenoviruses. A549 cells were mock-
infected or infected with the indicated adenovirus mutants at MOI of 5 (a) or 20 (b–d). (a) Twenty hours after infection or
camptothecin addition, p53 and the viral E2A protein were detected by immunoﬂuorescence and nuclei were visualized by 40,6-
diamidino-2-phenylindole. (b) Twenty-four hours after infection, the cells were harvested and subjected to immunoprecipitation (IP)
with conformation-speciﬁc antibodies to p53: 1620 for wild-type p53, 240 for mutant p53. p53 levels were detected by immunoblot
analysis (IB). C33A cells, bearing a p53 mutation recognized by the 240 antibody, p53 null H1299 cells, and the anti-T antigen antibody
419 served as controls. (c) Twenty-four hours after infection or camptothecin addition, the phosphorylation of p53 was analyzed by
immunoblot, staining with phospho-speciﬁc antibodies to p53. (d) The oligomerization state of p53 was assessed by glutaraldehyde
cross linking. Twenty-four hours after infection, the cells were harvested, treated with glutaraldehyde for 15min at the indicated
concentrations (%v/v), and subjected to SDS–PAGE. Cross-linked and monomeric p53 were then detected by immunoblot analysis
with the antibody 1801 to p53. p53 from virus-infected cells was compared with p53 from H1299 cells transfected to express wild type
p53 or the oligomerization mutant p53DO.
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interaction of CR3 with other proteins as additional
mechanistic bases for p53 inactivation. However, it is
intriguing that Sp1 has previously been found as a
critical determinant of p53 activity. Sp1 is required for
efﬁcient induction of p21 by p53 (Lagger et al., 2003;
Zhao et al., 2006), and the same is true when p53
induces Mdm2 expression. A cancer-associated poly-
morphism affects the interaction of Sp1 with the Mdm2
promoter, showing that this interaction is crucial for
proper regulation of p53 activity (Bond et al., 2004). For
activation of the proapoptotic targets PUMA and Bax,
p53 also cooperates with Sp1 (Thornborrow and
Manfredi, 2001; Koutsodontis et al., 2005; Wang
et al., 2008).
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Figure 5 Acetylation of p53 after infection with adenovirus
mutants. (a) A549 cells were mock-infected, infected with dl338,
dl520-E1B– or dl1101-E1B– at MOI 50, and/or treated with
camptothecin. Twenty-four hours after infection, immunoblot
analysis with antibodies to acetyl-p53 (K382) or global p53 was
performed. (b) A549 cells were mock-infected or treated with
camptothecin for 24 h, or infected with a recombinant adenovirus
that carries the mutation R240A in E1B-55 kDa, in combination
with the mutation R2G in E1A (resulting in strongly reduced p300
binding), at MOI 20 for 36 h. The cells were harvested and
subjected to immunoblot detection of acetylated or global p53 as
in a. (c) A549 cells were mock-infected or infected with the
indicated virus mutants at MOI 20. Thirty-six hours after infection,
p21 mRNA was quantiﬁed by RT–PCR and normalized to mt-
RNR2. Mean values from three independent experiments are
shown with standard deviations. (d) Suggested model for regulation
of p53 activity by adenovirus. Two distinct domains of E1A
independently interfere with p53-mediated transcription, blocking
p53 acetylation as well as the Sp1-DNA interaction. Note that the
two mechanisms each contribute to the ability of adenovirus to
attenuate the expression of p21/CDKN1A; their relative contribu-
tion (and that of other p53-regulatory mechanisms) may be
different for other p53-responsive genes. In any case, however,
E1A-13S is also required for the suppression of Mdm2 and PUMA
in adenovirus-infected cells (cf. Figure 3).
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Blockage of p53 acetylation by E1A
Adenovirus infection eliminated any detectable p53 acet-
ylation at K382, the major p300-acetylation site (Avantag-
giati et al., 1997; Lill et al., 1997; Ito et al., 2001). In
contrast, when the amino terminal, p300-binding region of
E1A (Harlow et al., 1986) was mutated in addition to E1B-
deletion, p53 not only accumulated in infected cells but also
displayed strong K382 acetylation. It is thus conceivable
that the interaction of the E1A-amino terminal region with
p300, the related CREB-binding protein (CBP), and
possibly P300/CBP-associated factor, contribute to the lack
of p53 acetylation. This is further supported by structural
analysis suggesting a competition of p53 and E1A for CBP
binding (Ferreon et al., 2009) and by the ability of E1A to
repress numerous genes with antivirus activity (Ferrari
et al., 2008). Thus, the amino terminal region and the CR3
of E1A provide at least two independent but cooperating
functions to antagonize p53 activity.
Post-transcriptional regulation of p53 levels
Adenovirus infection also affects the protein levels of
p53 and p21 independently of their mRNAs. The half-
life of p53 is strongly increased in response to infection
with E1B-less viruses. We suspect that the attenuated
expression of Mdm2 contributes to this phenomenon. In
addition, adenovirus E1A proteins were shown to block
proteasomal activity towards p53 by binding directly to
proteasomal subunits (Turnell et al., 2000). This effect
may be of particular importance in infected cells, as their
E1A levels are higher than in E1-transformed cells.
Multiple mechanisms for p53 inactivation
Two well-described mechanisms contribute to inactiva-
tion of p53 during adenovirus infection: direct binding
by E1B-55 kDa and ubiquitination mediated by E4-
34 kDa. Our study suggests that two additional mecha-
nisms attenuate p53 in infected cells, at least with regard
to p21 induction. Firstly, transcription and Sp1-DNA
association are impaired by E1A-CR3; secondly, p53
acetylation is abolished through the amino terminal,
p300-binding region of E1A. Subsets of these mechan-
isms are still sufﬁcient to prevent any detectable p53
activity. Perhaps, the parallel existence of these mechan-
isms provides an evolutionary advantage to the virus
only in the context of infected tissue, with intact immune
responses and associated proapoptotic mechanisms.
Indirect mechanisms to inactivate p53 are prevalent in
other viruses, too. Many non-oncogenic human papil-
lomaviruses lack the ability to degrade p53 through their
E6 gene products but still survived during evolution. In
these cases, indirect p53 inactivation by interaction of
E7 with p300 may prevent cell death (Bernat et al.,
2003). Herpes virus family members do not directly
antagonize p53 either, but at least in the case of
cytomegalovirus (human herpes virus type 5), the virus
protein IE2 binds p300 and thus attenuates p53 activity
(Hsu et al., 2004). The tat protein of human immuno-
deﬁciency virus also binds p300 and PCAF and it
attenuates p53 activity (Harrod et al., 2003; Wong et al.,
2005). Such indirect mechanisms may therefore sufﬁce
to avoid p53-induced cell death in many cases.
A role of p53 for oncolytic virus selectivity?
Adenoviruses lacking the interaction between E1B-
55 kDa and p53 have been examined for a long time
as to their ability to replicate selectively in tumor cells
with impaired p53 function, but with limited success.
The prototype virus employed for this purpose (Bischoff
et al., 1996) was later shown to display selectivity for
some tumor cells, but not based on p53 activity. Rather,
it takes advantage of differential mRNA export (O’Shea
et al., 2005). The results presented here provide an
explanation why the lack of E1B-55 kDa cannot be
expected to result in p53-selective cytotoxicity. The
question remains whether additional E1A mutations not
only restore p53 activity but also allow virus replication
preferentially in p53-mutant cells. In any case, however,
it should be kept in mind that E1A mutations may
reduce virus spread in tissues and hence result in a
tumor-selective, but generally attenuated virus with
limited therapeutic use.
p53 inactivation in the absence of adenovirus infection
Some of the mechanisms that directly attenuate p53 in
adenovirus-infected cells may also abolish the tumor-
suppressing function of p53 in cancer cells, especially
when the cellular Mdm2 protein (representing the
functional analog to E1B-55 kDa) is not sufﬁciently
expressed. Some cancer cells delete or mutate p300 and/
or CBP, and CBP-mutations form the basis for a
syndrome of cancer-proneness (Iyer et al., 2004),
arguing that p300/CBP inactivation and a resulting lack
in p53 acetylation may contributed to virus-independent
cancer as well. Moreover, the MYC family of oncopro-
teins shows many functional analogies to E1A. MYC
interacts with Sp1 and attenuates p21 expression (Gartel
et al., 2001); moreover, it binds p300 (Faiola et al.,
2005), perhaps modulating p53 acetylation. Finally, the
inactivation of p53 by adenovirus infection is reminis-
cent of the Chk1-dependent failure of p53 to activate
p21 expression during S-phase arrest (Gottifredi et al.,
2001; Beckerman et al., 2009). The mechanistic princi-
ples used by adenoviruses to attenuate p53 activity in
infected cells may thus serve as guidelines for the
deﬁnition of p53-inhibitory pathways in human cancer.
Materials and methods
Cell culture and drug treatment
A549, C33A and H1299 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium with 10% fetal bovine serum. Immortalized
keratinocytes, EPC-hTERT (Harada et al., 2003), were grown in
serum free medium with supplements (0.2ng/ml epidermal
growth factor and 25mg/ml bovine pituitary extract). Camp-
tothecin was used at 300nM, cycloheximide at 100mg/ml, AraC at
50mg/ml and mithramycin A at 1mg/ml.
Virus expansion and titration
The viruses under study were: human Ad5 parental virus dl309
(Jones and Shenk, 1979), its derivatives dl338 (Pilder et al.,
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1986) and R240A (Shen et al., 2001), bearing a deletion or a
point mutation in the E1B-55 kDa coding region, respectively;
E1B2xmut and E1AR2G, derived from R240A, carrying an
additional deletion of the E1B-19 kDa coding region or the
substitution R2G in E1A, respectively (Hobom and Dobbel-
stein, 2004); dl520-E1B– (encoding E1A-12S, but not E1A-13S
and lacking the E1B region) and its E1A-mutant derivatives
dl1101-E1B–, dl1107-E1B– and dl0107-E1B– (Shepherd et al.,
1993) were kindly provided by J S Mymryk, R J A Grand and
X. Zhang. E1A-13S-containing adenovirus mutants, bearing
either a deletion of E1B-55 kDa (dl110) or a double deletion of
E1B-55 kDa and E4-34 kDa (dl1017) (Bridge and Ketner,
1990) were obtained from G Ketner. An adenovirus vector,
lacking the entire E1 region but expressing b-galactosidase was
described (Koch et al., 2001). Viruses were grown in H1299 or
HER911 cells and titrated in A549 cells, as described previously
(Weigel and Dobbelstein, 2000). Virus stocks were stored in
phosphate-buffered saline. Mock infections (control experi-
ments) were performed by overlaying cells with phosphate-
buffered saline alone, rather than with virus suspensions.
Immunoblot analysis
After SDS–PAGE and semidry transfer to nitrocellulose, the
membranes were incubated with antibodies in phosphate-
buffered saline containing 5% non-fat milk powder and 0.1%
Tween 20. Primary antibodies used for detection were: anti-
p53 (DO1, Santa Cruz Biotechnology, Santa Cruz, CA, USA;
used for p53, unless indicated otherwise), anti-p53 (1801,
Santa Cruz), anti-phospho-Ser15 p53 (16G8), anti-phospho-
Ser46 p53, anti-acetyl-Lys382 p53 (all Cell Signaling Techno-
logy, Danvers, MA, USA), anti-p21 (EA10, Calbiochem/
Merck, Darmstadt, Germany), anti-Mdm2 (2A10, hybridoma
supernatant), anti-Sp1 (Upstate/Millipore, Billerica, MA,
USA), anti-E1A (13S-5, Santa Cruz), anti-Hexon (HPR
conjugated, Biogenesis Ltd., Poole, UK), anti-HSC70 (Santa
Cruz) and anti-b-actin (Abcam, Cambridge, MA, USA).
Detection was performed by HRP-conjugated antibodies
(Jackson, West Grove, PA, USA) and chemiluminescence
(Pierce/Thermo Scientiﬁc, Rockford, IL, USA).
Quantitative RT–PCR
RNA was isolated (Trizol, Invitrogen, Carlsbad, CA, USA),
reverse transcribed using the iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, USA) and subjected to real-time PCR with
the IQ SYBR Green Supermix (Bio-Rad). Primer sequences
are provided in the Supplementary Table S1.
Immunoﬂuorescence
Cells were ﬁxed with 4% paraformaldehyde, followed by
permeabilization with 0.2% Triton X-100 and blocking with
10% fetal bovine serum, all in phosphate-buffered saline. Cells
were co-stained with primary antibodies against p53 (rabbit
FL-393, Santa Cruz) and adenovirus E2A protein (mouse B6-
8, hybridoma supernatant), and secondary antibodies con-
jugated with Alexa Fluor 488 or Alexa Fluor 594 (Molecular
Probes/Invitrogen, Carlsbad, CA, USA).
Immunoprecipitation with conformation-speciﬁc antibodies
Cells were lysed in immunoprecipitation buffer (150mM NaCl,
50mM Tris-HCl, 5mM EDTA, 1% NP40) and subjected to
immunoprecipitation with 1 mg of antibodies (1620, 240, or
419, Calbiochem).
Oligomerization studies
Cells with wild-type or mutant p53 were harvested in lysis
buffer (140mM NaCl, 50mM Tris HCl pH 7.6, 0.5% NP40,
protein inhibitors; Roche, Basel, Switzerland), followed by
cross linking with glutaraldehyde (0.0025%, 0.01%) for
15min, and immunoblot analysis. The antibody 1801 (Santa
Cruz) was used for p53 detection.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described
previously (Braun et al., 2008) with the antibodies against p53
(DO1, Santa Cruz), Sp1 (Upstate/Millipore), RNA polymer-
ase II (N20, Santa Cruz, 1 mg) or the HA-tag (Santa Cruz;
control). The precipitated DNA was analyzed by quantitative
PCR with primers to the p21 promotor region (Supplementary
Table S1).
Note added in proof
While this paper was in press, another group reported
that infection with an adenovirus lacking E1B-55 kDa
results in the accumulation of inactive p53. Soria C,
Estermann FE, Espantman KC, O’Shea CC. Heterochromatin
silencing of p53 target genes by a small viral protein. Nature
466: 1076–1081.
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